Supernus Pharmaceuticals, Inc. (SUPN) Q4 2023 Earnings Results

Supernus Pharmaceuticals Misses on EPS, Stock Up 4.03%

Supernus Pharmaceuticals reported a significant miss on EPS, which typically raises concerns among investors. However, the stock rose by 4.03% on the day of the earnings release, indicating that investors may be optimistic about the company's long-term potential despite the disappointing earnings. The lack of revenue data and guidance leaves some uncertainty about future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.02	N/A	-95.12%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed cautious optimism about future prospects. They highlighted ongoing efforts to navigate current challenges.

Management acknowledged the challenges faced this quarter.

They emphasized a focus on long-term growth despite short-term setbacks.

Supernus Pharmaceuticals Misses on EPS, Stock Up 4.03%

Key numbers

Management commentary

Supernus Pharmaceuticals, Inc.

More earnings this week

Supernus Pharmaceuticals Misses on EPS, Stock Up 4.03%

Key numbers

Management commentary